Harrow (HROW) Cash from Financing Activities (2011 - 2026)

Harrow's (HROW) quarterly Cash from Financing Activities came in at $48.9 million in Q1 2026, up 212560.87% year-on-year from N/an in Q1 2025, and up 1069.71% quarter-over-quarter from -$5.0 million in Q4 2025.

Harrow (HROW) Cash from Financing Activities (2011 - 2026) Analysis & Trends

Harrow's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $48.9 million for Q1 2026.

  • On a quarterly basis, Cash from Financing Activities rose 212560.87% year-over-year to $48.9 million in Q1 2026; TTM through Mar 2026 was $36.2 million, a 23.18% increase from a year earlier, with the FY2025 full-year figure at -$12.7 million, down 144.6% from the prior year.
  • Cash from Financing Activities grew to $48.9 million in Q1 2026 per HROW's latest filing, from -$5.0 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $64.2 million in Q3 2023 and bottomed at -$12.7 million in Q2 2025.
  • The 5-year median for Cash from Financing Activities is $48000.0 (2024), against an average of $15.3 million.
  • Across the five-year window, Cash from Financing Activities surged 2751500.0% in 2022 and sank 17452.05% in 2025, its largest moves.
  • Year by year, Cash from Financing Activities stood at $55.0 million in 2022, then slumped by 100.03% to -$18000.0 in 2023, then soared by 166683.33% to $30.0 million in 2024, then plunged by 116.82% to -$5.0 million in 2025, then soared by 1069.71% to $48.9 million in 2026.
  • Per Business Quant, the three latest HROW Cash from Financing Activities figures stand at $48.9 million (Q1 2026), -$5.0 million (Q4 2025), and $5.0 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 13.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -840.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -494.13 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -1.48 Bn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn -203.80 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -86.10 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -65.00 Mn
10 Harrow 1.56 Bn 1.47 Bn 27.05 Mn 48.91 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 48.91 Mn
Mar 31, 2026 48.91 Mn
Dec 31, 2025 -5.04 Mn
Dec 31, 2025 -5.04 Mn
Sep 30, 2025 4.96 Mn
Sep 30, 2025 4.96 Mn
Jun 30, 2025 -12.67 Mn
Jun 30, 2025 -12.67 Mn
Mar 31, 2025 23,000.00
Mar 31, 2025 23,000.00
Dec 31, 2024 29.99 Mn
Dec 31, 2024 29.99 Mn
Sep 30, 2024 -721,000.00
Sep 30, 2024 -721,000.00
Jun 30, 2024 73,000.00
Jun 30, 2024 73,000.00
Mar 31, 2024 -809,000.00
Mar 31, 2024 -809,000.00
Dec 31, 2023 -18,000.00
Dec 31, 2023 -18,000.00